Related Experiment Video
Updated: Apr 16, 2026
07:29
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
9.9K
Lipoprotein(a)-clinical aspects and future challenges.
Bilgen Kurt1, Muhidien Soufi, Alexander Sattler
1Internal Medicine, Preventive Cardiology, University Clinic Gießen and Marburg, 35033, Marburg, Germany.
Clinical Research in Cardiology Supplements
|March 4, 2015
Summary
Lipoprotein(a) (Lp(a)) is linked to cardiovascular disease risk. While niacin trials failed, elevated Lp(a) confirms residual risk, necessitating aggressive LDL lowering and potentially aspirin.
Area of Science:
- Cardiovascular Science
- Lipidology
- Thrombosis
Background:
- Lipoprotein(a) (Lp(a)) combines LDL's atherogenic and plasminogen inactivation's thrombogenic properties.
- Historically, Lp(a)'s role in atherosclerosis was underestimated due to technical challenges and negative trials.
- Recent research has improved understanding of Lp(a)'s function and significance in cardiovascular health.
Purpose of the Study:
- To review the current understanding of Lipoprotein(a) (Lp(a))'s role in cardiovascular disease (CVD).
- To discuss the implications of past and ongoing research on Lp(a) management.
- To provide clinical recommendations for managing patients with elevated Lp(a).
Main Methods:
- Literature review of Lp(a) research, including historical context and recent findings.
- Analysis of interventional trial outcomes, specifically niacin's effect on Lp(a) and CVD risk.
- Evaluation of current and emerging therapeutic strategies for lowering Lp(a).
Main Results:
- Niacin interventions did not show benefit in lowering Lp(a) or reducing CVD events.
- Multiple studies confirm that elevated Lp(a) represents a significant residual cardiovascular disease risk.
- LDL/Lp(a) apheresis effectively lowers Lp(a) levels.
Conclusions:
- Despite past setbacks, elevated Lp(a) is a confirmed risk factor for cardiovascular disease.
- New pharmacological agents targeting Lp(a) are under development, requiring further clinical trials.
- Current clinical practice recommends aggressive LDL lowering and consideration of acetylsalicylic acid for patients with high Lp(a).
Related Concept Videos
01:30Atherosclerosis I: Introduction
2.2K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.2K
01:26Atherosclerosis III: Management
613
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
613
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
821
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
821
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
877
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
877
01:29Pharmacogenomics: Identification of New Drug Targets
95
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
95
01:30Peripheral Artery Disease I: Introduction
646
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
646